In summary, these results in primary MCL cells confirm that inhibition of POLΘ is effective for ATM-mutated MCL and that concurrent inhibition of ATM and POLΘ is a promising therapeutic strategy for ATM-proficient MCL. This evidence concerns the gene ATM and mantle cell lymphoma.